As GSK works on a nearly $1 billion expansion at one wing of its Pennsylvania operations, the U.K.-headquartered Big Pharma is unveiling a similarly sized outlay to soup up another site across the state.
All told, GSK is plugging more than $800 million into an overhaul of its facilities in Upper Merion Township, where construction is slated to kick off next year, according to an Oct. 9 release from the office of Pennsylvania Governor Josh Shapiro.
The goal is to set up a biopharma “innovation and manufacturing hub,” per the Governor’s release, which will ultimately wed commercial production and R&D activities at a single site with the aid of digital technologies.
On its website, GSK currently ranks Upper Merion among its U.S. R&D outposts, noting that the site “supports the discovery and development of medicines across multiple R&D disciplines.” Manufacturing work is currently performed in Upper Merion, too.
Rather than simply build out from what’s already present in Pennsylvania’s Montgomery County, GSK will demolish existing buildings to make way for “new and enhanced facilities,” Friday’s announcement continued. The biologics manufacturing facility GSK has in store will support both clinical and commercial-scale work, with the co-location of its planned R&D pilot plant expected to accelerate both tech transfer and process development.
Rounding things out will be a centralized quality control lab and manufacturing science and technology hub, according to the Governor’s announcement.
“Our Next Generation Flex Factory will focus on delivering potential best-in-class new medicines for respiratory disease and cancer for patients in the US and around the world,” said John Jewett, site director for GSK Upper Merion, in an emailed statement.
“This investment goes well beyond a single manufacturing building,” he continued, adding that GSK is “proud” of the role Upper Merrion plays in its global supply chain today, and “even more excited” about what the site could make possible after the expansion wraps.
GSK, whose U.S. headquarters is in Philadelphia, has a longstanding presence in the Keystone State, and its latest commitment is comparable in size to the expansion it unveiled at its Marietta site—a little over an hour’s drive west from Upper Merion—back in October 2024.
With that pledge, GSK also put forward up to $800 million to double the size and capacity of its Marietta production operations with the addition of two new facilities.
With new drug substance production and expanded drug product capabilities coming online there, GSK has said it expects the Marietta project to add around 200 new full-time positions once complete. The company previously communicated plans to debut its drug substance facility in Marietta by the end of 2027, with the drug product facility slated for operation in 2028.
Aside from the 300 new jobs expected from the Upper Merion upgrade, GSK’s latest investment could also help “retain” some 4,500 existing jobs in the state, the release from Shapiro pointed out.
Bigger picture, GSK is one of multiple large and mid-sized drugmakers to make public-facing manufacturing R&D and investment pledges in the U.S. since the second Trump administration in 2025.
Aside from ranking among the 26 pharmaceutical firms to ink a formal “most favored nation” agreement with the White House—exchanging certain drug pricing concessions for a period of immunity from President Donald Trump’s tariffs—GSK last September said that it would contribute $30 billion over the next five years to its U.S. R&D and manufacturing operations.
Plans for Upper Merion were already in the offing at that time, with GSK noting that $1.2 billion of its pledge were earmarked for advanced manufacturing, artificial intelligence and digital technologies, including the start of construction on its biologics “flex” factory in the Pennsylvania township.